{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:59Z","timestamp":1777507979543,"version":"3.51.4"},"reference-count":35,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Androgen deprivation therapy (ADT) is a fundamental component of treatment for metastatic hormone-sensitive prostate cancer (mHSPC), but it accelerates bone mineral density loss and increases fracture risk. International guidelines recommend calcium and vitamin D supplementation, baseline dual-energy X-ray absorptiometry (DXA), and antiresorptive therapy in patients with osteoporosis. Methods: We conducted a retrospective review of 156 mHSPC patients treated with ADT at a tertiary hospital between January 2022 and December 2024. We assessed adherence to guideline-recommended bone health measures. Collected variables included age, ADT duration, calcium\/vitamin D supplementation, DXA testing, antiresorptive treatment, and fracture events. Exploratory stratified analyses were performed, and proportions were reported with 95% confidence intervals (CIs). Results: Calcium\/vitamin D supplementation was prescribed in 50.6% of patients (95% CI: 42.9\u201358.4), baseline DXA was performed in 12.8% (95% CI: 8.5\u201318.9), and denosumab was administered in 5.1% of the cohort (95% CI: 2.6\u20139.8). The median follow-up was 23 months, with a fracture incidence of 0.67 events per 100 person-years. Stratified analyses showed lower adherence in older patients, those with prolonged ADT exposure, and those with high metastatic burden. Conclusions: Adherence to guideline-recommended bone health measures in patients with mHSPC receiving ADT was markedly suboptimal. These findings underscore the need to implement standardized institutional protocols to ensure systematic supplementation, routine DXA monitoring, and appropriate antiresorptive therapy.<\/jats:p>","DOI":"10.3390\/cancers17243977","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:32:37Z","timestamp":1765805557000},"page":"3977","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-9326","authenticated-orcid":false,"given":"Juan Antonio","family":"Encarnaci\u00f3n","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"},{"name":"Murcian Institute for Biosanitary Research \u201cPascual Parrilla\u201d, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-2096","authenticated-orcid":false,"given":"Jose Luis","family":"Alonso-Romero","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Murcian Institute for Biosanitary Research \u201cPascual Parrilla\u201d, 30120 Murcia, Spain"},{"name":"Department of Medical Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-2706","authenticated-orcid":false,"given":"Paula","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Murcian Institute for Biosanitary Research \u201cPascual Parrilla\u201d, 30120 Murcia, Spain"},{"name":"Department of Medical Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silverio","family":"Ros","sequence":"additional","affiliation":[{"name":"Murcian Institute for Biosanitary Research \u201cPascual Parrilla\u201d, 30120 Murcia, Spain"},{"name":"Department of Medical Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"De la Fuente","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Laborda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"S\u00e1nchez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Murcia, 30120 Murcia, Spain"},{"name":"Department of Radiation Oncology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Manso","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas Dario","family":"Ortega-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"L\u00f3pez-Cubillana","sequence":"additional","affiliation":[{"name":"Department of Urology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7248","authenticated-orcid":false,"given":"Pablo Luis","family":"Guzman Mart\u00ednez-Valls","sequence":"additional","affiliation":[{"name":"Department of Urology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Cao-Avellaneda","sequence":"additional","affiliation":[{"name":"Department of Urology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro \u00c1ngel","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Urology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-2694","authenticated-orcid":false,"given":"Alicia","family":"L\u00f3pez-Abad","sequence":"additional","affiliation":[{"name":"Department of Urology, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in PatientsWith Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castrationsensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues","volume":"25","author":"Bagrodia","year":"2009","journal-title":"Indian J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1464-410X.2008.07505.x","article-title":"Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer","volume":"102","author":"DiBlasio","year":"2008","journal-title":"BJU Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/jnci\/djae155","article-title":"Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors","volume":"116","author":"Faraj","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","first-page":"465","article-title":"Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer","volume":"166","author":"Shahinian","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.euo.2019.08.003","article-title":"Risk of dementia and depression in young and middle-aged men presenting with nonmetastatic prostate cancer treated with androgen deprivation therapy","volume":"4","author":"Tully","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_13","unstructured":"University of Washington (2025, July 06). RUCA Approximate Codes. University of Washington Department of Health Services. Available online: https:\/\/depts.washington.edu\/uwruca\/ruca-approx.php."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200107123450205","article-title":"Neighborhood of residence and incidence of coronary heart disease","volume":"345","author":"Merkin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"European Association of Urology (2024). EAU Guidelines on Prostate Cancer, EAU Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"ref_16","unstructured":"National Comprehensive Cancer Network (2024, January 5\u20137). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2024. Proceedings of the NCCN Plymouth Meeting, Plymouth, PA, USA. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1460."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO clinical practice guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"2201","article-title":"FRAX and fracture prediction without bone mineral density","volume":"35","author":"Kanis","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s11606-007-0291-4","article-title":"Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy","volume":"22","author":"Yee","year":"2007","journal-title":"J. Gen. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0002-9343(03)00357-7","article-title":"Underuse of osteoporosis medications in elderly patients with fractures","volume":"115","author":"Solomon","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100611","DOI":"10.1016\/j.jbo.2024.100611","article-title":"The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study)","volume":"47","author":"Handforth","year":"2024","journal-title":"J. Bone Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102438","DOI":"10.1016\/j.clgc.2025.102438","article-title":"Impact of Bisphosphonates in Hormone-sensitive Metastatic Prostate Cancer A systematic review and meta-analysis","volume":"23","author":"Polho","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e35606","DOI":"10.1002\/cncr.35606","article-title":"Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines","volume":"131","author":"Mousa","year":"2025","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jbmr.4821","article-title":"Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality","volume":"38","author":"Sing","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_29","first-page":"1200","article-title":"Incidence of Subsequent Hip Fracture and Mortality in Elderly Patients: A Multistate Population-Based Cohort Study in Eastern Spain","volume":"37","author":"Armero","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"J\u00fcrisson, M., Raag, M., Kallikorm, R., Lember, M., and Uusk\u00fcla, A. (2017). The Impact of Hip Fracture on Mortality in Estonia: A Retrospective Population-Based Cohort Study. BMC Musculoskelet. Disord., 18.","DOI":"10.1186\/s12891-017-1606-1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, L., Shuang, H., Qingjian, W., Jingzhen, Z., Ji, Z., and Yu, C. (2024). Bone health management in endocrine-treated patients with prostate cancer: A summary of evidence. BMC Urol., 24.","DOI":"10.1186\/s12894-024-01663-w"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Encarnaci\u00f3n, J.A., Morillo Mac\u00edas, V., De la Fuente Mu\u00f1oz, I., Soria, V.D., Fern\u00e1ndez Fornos, L., Antequera, M.A., Rey, O.A., Garc\u00eda Mart\u00ednez, V., Alonso-Romero, J.L., and Garc\u00eda G\u00f3mez, R. (2025). Apalutamide and Stereotactic Body Radiotherapy in Metastatic Hormone-Sensitive Prostate Cancer: Multicenter Real-World Study. Cancers, 17.","DOI":"10.3390\/cancers17132216"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Boegemann, M., Bennamoun, M., Dourthe, L.M., Encarnacion, J.A., Hegele, A., Hellmis, E., Latorzeff, I., Leicht, W., O\u00f1ate-Celdr\u00e1n, J., and Rosino-S\u00e1nchez, A. (2025). Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14294-7"},{"key":"ref_34","first-page":"20","article-title":"Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study","volume":"12","author":"Backhaus","year":"2023","journal-title":"Prostate Int."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Encarnaci\u00f3n Navarro, J.A., Morillo Mac\u00edas, V., Borr\u00e1s Calbo, M., De la Fuente Mu\u00f1oz, I., Lozano Mart\u00ednez, A., Garc\u00eda Mart\u00ednez, V., Fern\u00e1ndez Fornos, L., Guijarro Roche, M., Amr Rey, O., and Garc\u00eda G\u00f3mez, R. (2025). Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32030119"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3977\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:44:30Z","timestamp":1765806270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17243977"],"URL":"https:\/\/doi.org\/10.3390\/cancers17243977","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]}}}